In this study, we focused on the predominant NRAS mutations (Q61K/L/R) which makes up over 80% of the oncogenic NRAS mutations in melanoma, and systematically analyzed the potential pathways associated with these NRAS mutations by integrating DNA methylation, gene expression, and miRNA expression data. The gene discussed is NRAS; the disease is melanoma.